Dr. Sam Klempner discusses the use of circulating tumor DNA (ctDNA) testing to monitor for minimal residual disease (MRD) in GI cancer
· Education
In this session, Dr Sam Klempner from Massachusetts General Hospital discusses the use of circulating tumor DNA (ctDNA) testing to monitor for minimal residual disease (MRD) in GI cancer.
Get notified of new trials and updates
One email when something new is posted: a new clinical trial, meeting highlights, or educational material. No spam, unsubscribe any time.
Prefer a reader? Use the RSS feed.